In addition, three anti-IL17 biologics (ixekizumab, secukinumab, and brodalumab) and four anti-IL23 biologics (ustekinumab, guselkumab, risankizumab, and tildrakizumab) have been also marketed for the treatment of psoriasis via blocking the IL-23/Th17 axis. Here, IL17A is linked to psoriasis.